The cancer center at Children’s Hospital of Philadelphia brings together a multidisciplinary team of more than 1,000 experts who treat more than 5,600 patients annually. The center is consistently ranked among the nation’s top pediatric cancer centers by U.S. News & World Report and Newsweek. The center conducts nearly 600 research studies, more than any other U.S. pediatric hospital, across 19 specialized clinical programs covering the full range of childhood cancers and related conditions. It is also home to the Center for Precision Medicine for High-Risk Pediatric Cancer, which builds individualized treatment plans based on each patient’s specific vulnerabilities and therapeutic markers. In 2012, Children’s Hospital of Philadelphia treated the first pediatric gene therapy patient using CAR T-cell therapy for relapsed leukemia, a case that directly led to the first FDA-approved gene therapy in the U.S. in 2017. Since then, the hospital has treated more than 700 children with this therapy, more than any other hospital. CHOP continues to lead the field of cell and gene therapy, including securing FDA approval for the first two gene therapies for sickle cell disease.
